Post-Traumatic Stress Disorder Therapeutics Market Trends 2025-2029: Regional Outlook and Sizing Analysis

 Tailored for companies operating in or entering the post-traumatic stress disorder therapeutics sector, this analysis highlights core growth drivers, risks, and innovation trends.

How Fast Is The Post-Traumatic Stress Disorder Therapeutics Market Growing Towards 2025?
The post-traumatic stress disorder therapeutics market size has grown steadily in recent years. It will grow from $1.15 billion in 2024 to $1.2 billion in 2025 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to increased awareness, trauma incidence, government initiatives, advancements in diagnostic tools, stigma reduction, psychological support programs, veteran healthcare focus.

The post-traumatic stress disorder therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.36 billion in 2029 at a compound annual growth rate (CAGR) of 3.2%. The growth in the forecast period can be attributed to expanded access to mental health services, government mental health policies, biological and neurological research, PTSD in non-military populations, crisis response planning. Major trends in the forecast period include integration of digital therapeutics, advancements in pharmacological treatments, neurostimulation and brain stimulation techniques, psychedelic-assisted therapy, and collaborative research initiatives.

Get your free sample today:
Post-Traumatic Stress Disorder Therapeutics Market 2025, Size Sample

Post-Traumatic Stress Disorder Therapeutics Market Drivers And Opportunities
The rise in the burden of post-traumatic stress disorder (PTSD) cases across the globe are expected to propel the growth of the post-traumatic stress disorder therapeutics market going forward. Post-traumatic stress disorder refers to a disorder that develops in people who have experienced a scary, shocking, or dangerous event. Post-traumatic stress disorder treatment such as psychotherapy and medication can help to regain a sense of control over their life. For instance, in March 2024, according to the Ministry of Defence (MoD) Department of Community Mental Health (DCMH), a UK-based company that provides mental health services to serving personnel and reservists, a UK-based website covering defense industry news, the number of armed forces personnel receiving initial PTSD assessments by a specialist mental health clinician increased from 266 cases in 2022 to 320 cases in 2023, reflecting a significant rise in reported cases. Hence the rise in the burden of post-traumatic stress disorder (PTSD) cases is driving the growth of the post-traumatic stress disorder therapeutics market.

How Is The Post-Traumatic Stress Disorder Therapeutics Market Segmented?
The post-traumatic stress disorder therapeutics market covered in this report is segmented –

1) By Drug Class: Antidepressants, Anti-Anxiety, Antihypertensive, Monoamine Oxidase (MAOs), Antipsychotics Or Second Generation Antipsychotics (SGOs), Beta-Blockers, Other Classes
2) By Age Group: Pediatric, Geriatric, Adult
3) By End User: Mental Health Center, Hospitals, Outpatient Clinics, Other End Users

Subsegments:
1) By Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
2) By Anti-Anxiety: Benzodiazepines, Buspirone
3) By Antihypertensive: Prazosin, Clonidine
4) By Monoamine Oxidase Inhibitors (MAOs): Traditional MAOIs, Reversible MAOIs
5) By Antipsychotics (Second Generation Antipsychotics - SGOs): Risperidone, Quetiapine
6) By Beta-Blockers: Propranolol, Atenolol
7) By Other Classes: Mood Stabilizers, Adjunctive Therapies

What Are The Key Trends And Market Opportunities In The Post-Traumatic Stress Disorder Therapeutics Sector?
Strategic collaborations, funding, and investments have emerged as a key trend gaining popularity in the post-traumatic stress disorder therapeutics market. Major companies operating in the market are developing strategic collaborations and investing in the companies to strengthen their position in the market. For instance, in January 2022, Professor Dan Lubman AM, Dr. Shalini Arunogiri, and Dr. Paul Liknaitzky of Monash University, members of an interdisciplinary research team were given over $1.9 million to study the effectiveness of MDMA-assisted psychological treatment for treating alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD). The initiative is one of seven clinical studies under the Medical Research Future Fund (MRFF) unveiled this month by the Federal government to evaluate the use of potentially ground-breaking combination medicines to treat crippling mental diseases.

Major Companies Operating In The Post-Traumatic Stress Disorder Therapeutics Market Are:
Major companies operating in the post-traumatic stress disorder therapeutics market include Pfizer Inc., GlaxoSmithKline plc, Bionomics Limited, Otsuka Pharmaceutical Co Ltd., Eli Lilly and Company, AstraZeneca plc, Tonix Pharmaceuticals Holding Corp., Freespira Inc., MicroTransponder Inc., Compass Pathways plc, Boehringer Ingelheim International GmbH, Halucenex Life Sciences Inc., Bionorica SE, MAPS Europe BV, Hoffmann-La Roche Ltd., Praxis Precision Medicines Inc., H Lundbeck A/S, Johnson & Johnson, Sanofi SA, Takeda Pharmaceutical Company Limited, Merck KGaA, Jazz Pharmaceuticals plc

View the full post-traumatic stress disorder therapeutics market report here:
Post-Traumatic Stress Disorder Therapeutics Market 2025, Size

Regional Analysis: Opportunities And Challenges In The Post-Traumatic Stress Disorder Therapeutics Market
North America was the largest region in the post-traumatic stress disorder therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-traumatic stress disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Contact Us:

The Business Research Company

Market Research Reports

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: The Business Research Company | LinkedIn